Nektar’s stock doubles on eczema therapy success in Phase IIb study
In 2023, Nektar accused its development partner Eli Lilly of publishing "erroneous data" in rezpeg.
25 June 2025
25 June 2025
In 2023, Nektar accused its development partner Eli Lilly of publishing "erroneous data" in rezpeg.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.